These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 9558349)

  • 1. NADPH-flavodoxin reductase and flavodoxin from Escherichia coli: characteristics as a soluble microsomal P450 reductase.
    Jenkins CM; Waterman MR
    Biochemistry; 1998 Apr; 37(17):6106-13. PubMed ID: 9558349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flavodoxin and NADPH-flavodoxin reductase from Escherichia coli support bovine cytochrome P450c17 hydroxylase activities.
    Jenkins CM; Waterman MR
    J Biol Chem; 1994 Nov; 269(44):27401-8. PubMed ID: 7961651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negatively charged anabaena flavodoxin residues (Asp144 and Glu145) are important for reconstitution of cytochrome P450 17alpha-hydroxylase activity.
    Jenkins CM; Genzor CG; Fillat MF; Waterman MR; Gómez-Moreno C
    J Biol Chem; 1997 Sep; 272(36):22509-13. PubMed ID: 9278403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The function of recombinant cytochrome P450s in intact Escherichia coli cells: the 17 alpha-hydroxylation of progesterone and pregnenolone by P450c17.
    Shet MS; Fisher CW; Estabrook RW
    Arch Biochem Biophys; 1997 Mar; 339(1):218-25. PubMed ID: 9056252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escherichia coli flavodoxin sepharose as an affinity resin for cytochromes P450 and use to identify a putative cytochrome P450c17/3beta-hydroxysteroid dehydrogenase interaction.
    Jenkins CM; Pikuleva I; Kagawa N; Waterman MR
    Arch Biochem Biophys; 1997 Nov; 347(1):93-102. PubMed ID: 9344469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of NADPH-P450 reductase with P450: an electrochemical study of the role of the flavin mononucleotide-binding domain.
    Estabrook RW; Shet MS; Fisher CW; Jenkins CM; Waterman MR
    Arch Biochem Biophys; 1996 Sep; 333(1):308-15. PubMed ID: 8806785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The flavoprotein component of the Escherichia coli sulfite reductase can act as a cytochrome P450c17 reductase.
    Zeghouf M; Defaye G; Fontecave M; Coves J
    Biochem Biophys Res Commun; 1998 May; 246(3):602-5. PubMed ID: 9618257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of flavodoxin NADP+ oxidoreductase and flavodoxin; key components of electron transfer in Escherichia coli.
    McIver L; Leadbeater C; Campopiano DJ; Baxter RL; Daff SN; Chapman SK; Munro AW
    Eur J Biochem; 1998 Nov; 257(3):577-85. PubMed ID: 9839946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid 17 alpha-hydroxylase and 17,20-lyase activities of P450c17: contributions of serine106 and P450 reductase.
    Lin D; Black SM; Nagahama Y; Miller WL
    Endocrinology; 1993 Jun; 132(6):2498-506. PubMed ID: 8504753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the 17 alpha-hydroxylase/C17,20-lyase activities of porcine, guinea pig and bovine P450c17 using purified recombinant fusion proteins containing P450c17 linked to NADPH-P450 reductase.
    Shet MS; Fisher CW; Tremblay Y; Belanger A; Conley AJ; Mason JI; Estabrook RW
    Drug Metab Rev; 2007; 39(2-3):289-307. PubMed ID: 17786622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5.
    Geller DH; Auchus RJ; Miller WL
    Mol Endocrinol; 1999 Jan; 13(1):167-75. PubMed ID: 9892022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P450BM-3; a tale of two domains--or is it three?
    Peterson JA; Sevrioukova I; Truan G; Graham-Lorence SE
    Steroids; 1997 Jan; 62(1):117-23. PubMed ID: 9029725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Homodimer Model Can Resolve the Conundrum as to How Cytochrome P450 Oxidoreductase and Cytochrome b5 Compete for the Same Binding Site on Cytochrome P450c17.
    Holien JK; Parker MW; Conley AJ; Corbin CJ; Rodgers RJ; Martin LL
    Curr Protein Pept Sci; 2017; 18(5):515-521. PubMed ID: 28000554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four crystal structures of the 60 kDa flavoprotein monomer of the sulfite reductase indicate a disordered flavodoxin-like module.
    Gruez A; Pignol D; Zeghouf M; Covès J; Fontecave M; Ferrer JL; Fontecilla-Camps JC
    J Mol Biol; 2000 May; 299(1):199-212. PubMed ID: 10860732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical differences between rat and human cytochrome P450c17 support the different steroidogenic needs of these two species.
    Brock BJ; Waterman MR
    Biochemistry; 1999 Feb; 38(5):1598-606. PubMed ID: 9931027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression in Escherichia coli of functional cytochrome P450c17 lacking its hydrophobic amino-terminal signal anchor.
    Sagara Y; Barnes HJ; Waterman MR
    Arch Biochem Biophys; 1993 Jul; 304(1):272-8. PubMed ID: 8323292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a simple and rapid assay for the evaluation of inhibitors of human 17alpha-hydroxylase-C(17,20)-lyase (P450cl7) by coexpression of P450cl7 with NADPH-cytochrome-P450-reductase in Escherichia coli.
    Ehmer PB; Jose J; Hartmann RW
    J Steroid Biochem Mol Biol; 2000 Dec; 75(1):57-63. PubMed ID: 11179909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equilibrium and transient state spectrophotometric studies of the mechanism of reduction of the flavoprotein domain of P450BM-3.
    Sevrioukova I; Shaffer C; Ballou DP; Peterson JA
    Biochemistry; 1996 Jun; 35(22):7058-68. PubMed ID: 8679531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH--cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates.
    Yamazaki H; Ueng YF; Shimada T; Guengerich FP
    Biochemistry; 1995 Jul; 34(26):8380-9. PubMed ID: 7599128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human cytochrome P450 1A2 and an N-terminal-truncated form: construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase.
    Dong MS; Yamazaki H; Guo Z; Guengerich FP
    Arch Biochem Biophys; 1996 Mar; 327(1):11-9. PubMed ID: 8615680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.